Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2018-05-16
DOI
10.1080/10428194.2018.1457147
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
- (2018) Simon Schliffke et al. OncoImmunology
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
- (2017) Qingsong Yin et al. JOURNAL OF IMMUNOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
- (2017) Mara Compagno et al. NATURE
- The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
- (2017) Lingyan Ping et al. Oncotarget
- Idelalisib in the management of lymphoma
- (2016) C. Y. Cheah et al. BLOOD
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib
- (2016) Inhye E. Ahn et al. BLOOD
- LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia
- (2016) Phuong-Hien Nguyen et al. CANCER CELL
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2016) C. Vitale et al. HAEMATOLOGICA
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation
- (2016) Kah-Lok Chan et al. LEUKEMIA & LYMPHOMA
- Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors
- (2016) Karthik V. Giridhar et al. LEUKEMIA & LYMPHOMA
- Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade
- (2016) Sarah E.M. Herman et al. SEMINARS IN ONCOLOGY
- Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2016) C. Vitale et al. HAEMATOLOGICA
- Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
- (2016) Clare Sun et al. JAMA Oncology
- Idelalisib-associated Colitis
- (2015) Anna-Sophie Weidner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) C. Sun et al. BLOOD
- Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
- (2015) M. Skarzynski et al. CLINICAL CANCER RESEARCH
- Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
- (2015) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function
- (2015) Li Ren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo
- (2015) B S Hanna et al. LEUKEMIA
- Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature
- (2015) Stefano Molica et al. LEUKEMIA & LYMPHOMA
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer
- (2015) A. J. Gunderson et al. Cancer Discovery
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
- (2014) R. Jitschin et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages
- (2014) P. Giannoni et al. HAEMATOLOGICA
- Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
- (2014) F. D. Roit et al. HAEMATOLOGICA
- Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells
- (2014) Julio Gomez-Rodriguez et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival
- (2014) M. Melcher et al. JOURNAL OF IMMUNOLOGY
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells
- (2013) S. Nagaraj et al. JOURNAL OF IMMUNOLOGY
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia
- (2012) Francesco Maura et al. AMERICAN JOURNAL OF HEMATOLOGY
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
- (2012) J. C. Riches et al. BLOOD
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils
- (2012) Fumiko Honda et al. NATURE IMMUNOLOGY
- Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
- (2011) X. C. Badoux et al. BLOOD
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Association of an increased frequency of CD14+HLA-DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)
- (2011) Michael P. Gustafson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia
- (2010) K. Fiedler et al. BLOOD
- Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) 2 and PI3K pathways
- (2010) H. Mueller et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ
- (2010) Jennifer K. Uno et al. GASTROENTEROLOGY
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis
- (2009) Clive S. Zent et al. LEUKEMIA & LYMPHOMA
- Regulation of p110δ PI 3-Kinase Gene Expression
- (2009) Klaartje Kok et al. PLoS One
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started